Sign in Sign up for free

Last updated: 7 June 2024 at 5:20pm EST

Glenn Pierce Net Worth




The estimated Net Worth of Glenn Pierce is at least $1.79 Million dollars as of 14 July 2022. Glenn Pierce owns over 9,512 units of Global Blood Therapeutics stock worth over $1,149,810 and over the last 9 years he sold GBT stock worth over $63,730. In addition, he makes $579,495 as Independent Director at Global Blood Therapeutics.

Glenn Pierce GBT stock SEC Form 4 insiders trading

Glenn has made over 5 trades of the Global Blood Therapeutics stock since 2018, according to the Form 4 filled with the SEC. Most recently he sold 9,512 units of GBT stock worth $63,730 on 14 July 2022.

The largest trade he's ever made was exercising 15,000 units of Global Blood Therapeutics stock on 10 September 2020 worth over $225,450. On average, Glenn trades about 1,648 units every 61 days since 2016. As of 14 July 2022 he still owns at least 16,788 units of Global Blood Therapeutics stock.

You can see the complete history of Glenn Pierce stock trades at the bottom of the page.





Glenn Pierce biography

Dr. Glenn F. Pierce M.D. Ph.D. serves as Independent Director of the Company. In February 2016, Dr. Pierce joined Third Rock Ventures, a venture capital firm, as an independent consultant and entrepreneur-in-residence. In 2018, Dr. Pierce co-founded Ambys Medicines, a biopharmaceutical company, and currently serves as Chief Medical Officer. He also serves on the World Federation of Hemophilia (WFH) Board and the National Hemophilia Foundation (NHF) (US) Medical and Scientific Advisory Council. Dr. Pierce is also a director of Voyager Therapeutics, a biopharmaceutical company. Dr. Pierce retired from Biogen in 2014 as senior vice president of Hematology, Cell and Gene Therapies. He had overall R&D responsibility for hemophilia and hemoglobinopathies and served as Chief Medical Officer since joining the company in 2009. Dr. Pierce was also responsible for global medical affairs for Biogen’s portfolio from 2012 to 2014. Dr. Pierce has 30 years’ experience in biotechnology research and development, beginning at Amgen, is the co-author of more than 150 scientific papers and is a named inventor in over 15 patents. Dr. Pierce also served on the Blood Products Advisory Committee at the United States Food and Drug Administration and the Committee on Blood Safety and Availability at the United States Department of Health and Human Services. He received an M.D. and a Ph.D. in Immunology, both from Case Western Reserve University in Cleveland, Ohio and did his postgraduate training in pathology and hematology research at Washington University in St. Louis, Missouri. Dr. Pierce’s qualifications to serve on our Board of Directors include nearly 30 years of experience in leading biotechnology research and development in small, large, public and private biotechnology and biopharmaceutical firms.

What is the salary of Glenn Pierce?

As the Independent Director of Global Blood Therapeutics, the total compensation of Glenn Pierce at Global Blood Therapeutics is $579,495. There are 17 executives at Global Blood Therapeutics getting paid more, with Ted Love having the highest compensation of $10,097,200.



What's Glenn Pierce's mailing address?

Glenn's mailing address filed with the SEC is C/O VOYAGER THERAPEUTICS, INC., 75 HAYDEN AVENUE, LEXINGTON, MA, 02421.

Insiders trading at Global Blood Therapeutics

Over the last 9 years, insiders at Global Blood Therapeutics have traded over $164,753,446 worth of Global Blood Therapeutics stock and bought 255,000 units worth $8,595,265 . The most active insiders traders include Advisors Llcperceptive Life..., Rock Ventures Ii, L.P.Third..., and Kevin P Starr. On average, Global Blood Therapeutics executives and independent directors trade stock every 14 days with the average trade being worth of $3,133,144. The most recent stock trade was executed by Nazila Habibizad on 1 October 2022, trading 1,557 units of GBT stock currently worth $106,639.



What does Global Blood Therapeutics do?

Global Blood Therapeutics (GBT) is a biopharmaceutical company dedicated to the discovery, development, and delivery of life-changing treatments that provide hope to underserved patient communities. Founded in 2011, GBT is delivering on its goal to transform the treatment and care of sickle cell disease (SCD), a lifelong, devastating inherited blood disorder. The company has introduced Oxbryta® (voxelotor) tablets, the first FDA-approved treatment that directly inhibits sickle hemoglobin polymerization, the root cause of red blood cell sickling in SCD. GBT is also advancing its pipeline program in SCD with inclacumab, a P-selectin inhibitor in development to address pain crises associated with the disease, and GBT021601 (GBT601), the company's next generation hemoglobin S polymerization inhibitor. In addition, GBT's drug discovery teams are working on new targets to develop the next wave of treatments for SCD.



What does Global Blood Therapeutics's logo look like?

Global Blood Therapeutics Inc. logo

Complete history of Glenn Pierce stock trades at Global Blood Therapeutics and Voyager Therapeutics Inc

Date
#
Company
 Insider
Trans.
Transaction
 Shares Price per share Total value Shares after Source
14 Jul 2022 VYGR Voyager Therapeutics Inc Glenn Pierce
Director
 Sale 9,512 $6.70 $63,730
14 Jul 2022
16,788 ↗
12 Sep 2018 VYGR Voyager Therapeutics Inc Glenn Pierce
Director
 Buy 5,000 $18.44 $92,200
12 Sep 2018
5,000 ↗
14 Jun 2022 GBT Global Blood Therapeutics Inc. Glenn Pierce
Director
 Option 3,600 $22.30 $80,280
14 Jun 2022
26,437 ↗
10 Sep 2020 GBT Global Blood Therapeutics Inc. Glenn Pierce
Director
 Option 15,000 $15.03 $225,450
10 Sep 2020
19,800 ↗
17 Jun 2020 GBT Global Blood Therapeutics Inc. Glenn Pierce
Director
 Option 4,800 $64.75 $310,800
17 Jun 2020
4,800 ↗


Global Blood Therapeutics executives and stock owners

Global Blood Therapeutics executives and other stock owners filed with the SEC include: